HbA1c ReductionGastric bypass

Clinical evidence dossier

Gastric bypass

HbA1c

Evidence signal

Evidence signal

Moderate

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
3
Supporting studies available for review
3
Randomized trials
2
Reported effects
6

Clinical conclusion

Gastric bypass shows a strong positive evidence signal for improving HbA1c across the studied comparisons.

The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Absolute change

−2.18% to −2.18%

1 eligible estimates52–52 weeksObserved median: −2.18%

Evidence composition

Non-randomized studies
1
Other designs
0
Unresolved designs
0
Magnitude-eligible effects
1

Consistency

Consistency classification

Consistent

Positive
3
No effect
0
Mixed
0
Negative
0

Population and applicability

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Adults diagnosed with Type 2 diabetes.
  • Individuals seeking weight loss through medical or surgical interventions.
  • Obese individuals aged 18-65 with type 2 diabetes.
  • Patients who have not achieved glycemic control through lifestyle changes.
  • Young Adult (19–39)
  • Middle Aged (40-64)
  • Male
  • Female
  • with T2 Diabetes

Limitations

  • Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.
  • 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence